On Thursday, LivaNova earned an upgrade to its Relative Strength (RS) Rating, from 69 to 76.
How To Invest In Stocks In Both Bull And Bear Markets
This exclusive rating from Investor's Business Daily measures market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price performance over the last 52 weeks compares to all the other stocks in our database.
History shows that the best stocks often have an 80 or better RS Rating in the early stages of their moves. See if LivaNova can continue to rebound and hit that benchmark.
LivaNova is working on a cup without handle with a 57.35 buy point. See if the stock can clear the breakout price in volume at least 40% above average.
EPS growth fell in the company's most recent report from 21% to 13%, but the top line rose from 7% to 11%.
The company earns the No. 7 rank among its peers in the Medical-Products industry group. Insulet, TransMedics Group and ResMed are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
